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Type 2 diabetes is a major health problem in the 
21st century, with increasing rates of obesity both 
driving up the number of patients affected and 
reducing the age at diagnosis. Drugs that lower 
the blood glucose level in patients with type 2 dia-
betes reduce symptoms and the risk of long-term 
complications. The progressive nature of the 
hyperglycemia and the failure of drugs to alter 
the rate of this progression mean that, with time, 
increasing numbers of agents are usually required 
to maintain glycemic control. Recently, a plethora 
of glucose-lowering agents have become avail-
able. These drugs have different mechanisms, 
and for each there exists a balance between their 
desired effect — lowering the blood glucose 
level — and their undesired side effects.
One recently approved class of glucose-low-
ering drugs inhibits the low-affinity (high KM), 
sodium-coupled glucose transporter type 2 (SGLT2) 
in the renal proximal tubule and hence reduces 
the renal reabsorption of filtered glucose, result-
ing in substantial glycosuria. The loss of glucose 
in the urine both lowers the blood glucose level 
and results in weight loss owing to caloric loss. 
The major side effects reflect increased glycos-
uria, with increased incidence of genitourinary 
infections (especially candida infection) and poly-
uria and an increased risk of dehydration. A re-
cent study by Bonner and colleagues1 suggests 
that SGLT2 inhibitors also increase the secretion 
of glucagon by means of a direct effect on the 
alpha cell.
Glucagon is a peptide hormone, produced by 
alpha cells of the pancreatic islet, that raises the 
blood glucose level and opposes the glucose-
lowering action of insulin, which is secreted by 
the neighboring beta cells. Glucagon secretion is 
induced by hypoglycemia to stimulate hepatic 
glucose production and restore normoglycemia. 
In persons with type 2 diabetes, fasting gluca-
gon secretion is abnormally increased, leading 
to elevated hepatic glucose production and con-
tributing to fasting hyperglycemia.
The control of glucagon secretion is complex 
and still incompletely understood. It involves 
alpha-cell glucose-signaling mechanisms, islet 
paracrine regulation by insulin, and autonomic 
nervous control.2 Alpha-cell glucose sensing de-
pends on glucose uptake and metabolism, chang-
es in the ratio of intracellular ATP to ADP, and 
the control of the activity of the sulfonylurea-
sensitive ATP-sensitive potassium (KATP) channel. 
In the presence of low levels of glucose, the ac-
tivity of the KATP channel is low, which allows 
Ca2+ entry through P/Q-type channels, resulting 
in glucagon secretion. At high glucose concen-
trations, the activity of the KATP channel is fully 
suppressed, preventing the activation of P/Q-type 
Ca2+ channels and thereby reducing glucagon 
secretion. Glucose uptake by alpha cells is there-
fore the first and critical step in glucose signal-
ing and, until the report by Bonner and col-
leagues, was thought to be solely controlled by 
the glucose transporter GLUT-1 (Fig. 1).3
Bonner et al. also found that alpha cells ex-
press the sodium–glucose cotransporters SGLT1 
and SGLT2, and they propose that the inhibition 
of SGLT2 results in increased secretion of gluca-
gon. Their study results are supported by the 
observations that the treatment of patients with 
type 2 diabetes with SGLT2 inhibitors unexpect-
edly increases hepatic glucose production and 
plasma glucagon levels.4,5 Bonner et al. found 
that the SGLT2 inhibitor dapagliflozin can in-
deed induce glucagon secretion by isolated human 
and mouse islets and that when dapaglif lozin 
was administered to mice, their plasma gluca-
gon levels rapidly increased. Thus, the inhibition 
of SGLT2 induces glucagon secretion. They fur-
ther found that SGLT2 expression is reduced and 
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glucagon expression increased in the islet in 
patients with type 2 diabetes and in islets from 
persons without diabetes who had exposure to 
chronic hyperglycemia.
The article by Bonner et al. raises as many 
questions as it answers, and it emphasizes how 
poorly we understand the regulation of glucagon 
secretion in the alpha cell. In addition to SGLT2, 
alpha cells also express the alternative glucose 
transporters GLUT-1 and SGLT1, which should 
allow glucose transport when SGLT2 is inhibited. 
Why would a cotransport system that concen-
trates glucose be used to control glucagon se-
cretion, which is important in the response to 
Figure 1. Renal Absorption of Glucose and Glucagon Secretion According to the Presence or Absence of a Sodium-Coupled Glucose 
Transporter Type 2 (SGLT2) Inhibitor.
SGLT2 has actions in the renal proximal tubule cell (left side in Panels A and B) and also the alpha cell (right side in both panels). In the 
renal proximal tubule cell, SGLT2 inhibition (Panel B) results in a reduction of glucose reabsorption by the kidney, which increases gly-
cosuria and reduces the blood glucose concentration. In the alpha cell at high glucose concentrations (Panel A), the intracellular ratio of 
ATP to ADP increases, closing the ATP-sensitive potassium (KATP) channel, preventing the activation of P/Q-type Ca2+ channels, and re-
ducing glucagon secretion. Bonner et al.1 found that the inhibition of SGLT2 (e.g., with dapagliflozin) can induce glucagon secretion. 
This is thought to be mediated by a reduction in glucose uptake, which in turn reduces the intracellular ratio of ATP to ADP, thereby 
opening the KATP channel, activating P/Q-type Ca2+ channels, and increasing glucagon secretion. Thus, the inhibition of SGLT2 induces 
glucagon secretion, thereby increasing the hepatic glucose output, which in turn increases the blood glucose concentration. Because 
 alpha cells also express the facilitated diffusion glucose transporter GLUT-1 and the sodium–glucose cotransporter SGLT1, which trans-
ports two Na+ for one glucose, the data from Bonner et al. showing a dominant role of SGLT2 in the control of glucagon secretion are 
surprising.
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hypoglycemia, when the concentrating action of 
these transporters may lead to intracellular glu-
cose concentrations that do not reflect the extra-
cellular ones?
What does this mean for the clinician consid-
ering an SGLT2 inhibitor to treat a patient with 
type 2 diabetes? The increased glucagon secretion 
that results from SGLT2 acting as an alpha-cell 
secretagogue will mean that the glucose level 
will fall less than would be anticipated given the 
degree of urinary glucose loss.4,5 This reduced 
fall in the blood glucose level for the degree of 
glycosuria matters because it is glycosuria that 
results in most of the symptoms of diabetes — 
polyuria, polydipsia, weight loss, and genitouri-
nary infection. So, with SGLT2 inhibitors, a re-
duction in a patient’s glucose level needs to be 
balanced against the increase in severity of their 
diabetes-related symptoms, whereas with other 
agents the reduction in the patient’s glucose 
level is associated with a reduction in the sever-
ity of their diabetes-related symptoms.
Can other therapy counteract the increased 
glucagon secretion? The hypoglycemic effect of 
sulfonylureas and glucagon-like peptide 1 (GLP-1)–
receptor agonists depends in part on their abil-
ity to reduce glucagon secretion. Interestingly, 
dapagliflozin-induced glucagon secretion can be 
suppressed by low levels of tolbutamide, which 
further supports the hypothesis that each of these 
drugs counters the effect of the other with re-
gard to glucagon secretion, at different steps of 
the glucose-signaling pathway (which regulates 
glucagon secretion). Coprescribing of low-dose 
sulfonylureas with GLP-1–receptor agonists in 
order to prevent the rise in glucagon secretion 
could result in a marked reduction in glycemia 
but at the risk of increased hypoglycemia. This 
therapeutic option needs direct investigation.
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